Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper
New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples
Could a different testing strategy reduce healthcare workers’ isolation after unprotected exposure to a confirmed case of COVID-19?
RI-MUHC study suggests appropriate...
The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients
Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects
Driving Personalized Medicine: The 2020 RI-MUHC Annual Report is online!
An invitation from Dr. Miguel Burnier Jr.
What do we know about sleep apnea, pregnancy and gestational diabetes?
RI-MUHC researchers find link that may lead to better health for mother and baby
Stem cells are the marrow of the TB pandemic, which still kills one person every 22 seconds
A new study finds that not only can stem cells be targeted for protective vaccination, but they can also ...
Sleep apnea treatment reduces heart problems in patients with prediabetes, a new study finds
People with prediabetes and obstructive sleep apnea could reduce their daytime resting heart rate and risk of cardiovascular disease by using a CPAP machine at night
Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening
RI-MUHC researcher Maziar Divangahi honoured by the Royal Society of Canada
Recognition for high-level achievement in research into pulmonary infectious diseases
Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations
Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet
Canada Research Chairs Program announces new and renewed chairs
Congratulations to five RI-MUHC researchers in the spring 2020 round!
Recipient of the 2020-2021 Dr. Margaret Becklake Fellowship: Mikashmi Kohli
A postdoctoral fellow from the RI-MUHC is recognized for international work on TB diagnostics
Three COVID-19 projects at the RI-MUHC to receive CIHR funding
A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease
Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis
Why do some non-smokers get COPD while many heavy smokers don’t?
A new study highlights a strong risk factor for COPD related to lung development
Results of MI4 Emergency COVID-19 Research Funding (Round 2)
RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe
We Care About Rare!
Researchers, advocates and patients gather on Rare Disease Research Day at the RI-MUHC
RI-MUHC investigator joins Global Consortium of Chemosensory Researchers (GCCR) in rapid response to COVID-19
GCCR group develops worldwide survey on smell loss